2023-03-08 17:20:45 ET
- OptimizeRx ( NASDAQ: OPRX ) is down ~19% in after-hours trading after its Q4 2022 revenue results missed expectations and its 2023 revenue growth guidance came in well below consensus.
- In 2023, the company said it expects net revenues to increase at least 10% year over year. Consensus is expecting 20.5% year-over-year growth.
- In Q1 2023, OptimizeRx ( OPRX ) is expecting revenue between $11.5M and $13M. For the year, the consensus estimate is $77.8M.
- In Q4 2022, OptimizeRx ( OPRX ) swung to a net loss ~$325.8K from a net income of ~$623.5K in the year-ago period ($0.25 non-GAAP diluted per share vs $0.22).
- The company ended 2022 with ~$18.2M in cash and cash equivalents compared to ~$84.7M at the end of 2021.
- Seeking Alpha's Quant Rating views OptimizeRx ( OPRX ) as a hold with high marks for growth and profitability .
For further details see:
OptimizeRx Q4 top line miss, lackluster 2023 revenue guidance drives shares down 19%